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ABSTRACT 
 
INTRODUCTION 
 
Immunoglobulin light chain (AL) amyloidosis is a progressive plasma cell dyscrasia which is characterized 
by deposition of amyloid fibers derived from immunoglobulin light chain systemically in many organs 1. 
Amyloidogenic light chains are secreted by clonal plasma cells and, because of the immunoglobulin 
variability, they are unique to each patient 2, 3. Characteristics of amyloids related to disease severity and 
sequelae, including the target organs where amyloids accumulate, such as the heart, kidney, liver and 
peripheral nerves 3. Heart failure is usually the critical life-threatening condition; the median survival time 
depends on the extent of amyloid interference with the critical organ function and survival may range from 
some months to some years 1, 4. The incidence in AL amyloidosis is estimated to be somewhat over 3 per 
million 5, 6. Monoclonal gammopathy of undetermined significance (MGUS) is often the precursor disease 
for AL amyloidosis and the related disease multiple myeloma (MM) 7. It has been reported that some 10 to 
15% of multiple myeloma patients have AL amyloidosis 8, 9; conversely, some 10% of AL amyloidosis 
patients have MM at the time of diagnosis 10. AL amyloidosis and MM share genetic risk loci and the 7 
single nucleotide polymorphism (SNPs) initially described for MM were replicated in 443 AL amyloidosis 
patients with a nominal significance of p<0.05 11. 
 
We have recently characterized 10 putative genetic risk loci (at significance level of <10-5) for AL 
amyloidosis using a genome-wide association study (GWAS) approach on a total of 1351 German, UK and 
Italian patients 12. In the present study we carry out a systematic association study on the GWAS identified 
loci and the available clinical data including the affected organs and the type of serum immunoglobulin (Ig).  
 
METHODS 
  
The patient populations and GWAS analysis have been described elsewhere 12. Shortly, the German 
amyloidosis patients (595 passed the GWAS quality control) were ascertained through the Amyloidosis 
Center at University Clinic Heidelberg. The UK samples (474) were obtained from the National Amyloidosis 
Centre, London and the Italian samples (282) came from the Amyloidosis Research and Treatment Center, 
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Pavia. The diagnostic criteria used were as described 13. DNA was genotyped using Illumina Human 
OmniExpress-12 v1.0 and related arrays. Local control populations included 2,107 Germans, 5637 Britons 
465 Italians. 
 
A total of 9 clinical profiles were selected among organ involvement (kidney, heart, heart & kidney and liver, 
irrespective of whether other organs were involved) and Ig profiles (IgG with intact Ig, λ any, κ any, λ/κ light 
chain only (LCO), and λ LCO).   
 
Analysis of the GWAS data was performed using imputed data as described 12. All SNPs having a minor 
allele frequency (MAF) <1% were excluded. The association test between imputed SNPs and AL 
amyloidosis was performed in SNPTESTv2.5. The three data sets were combined in meta-analysis and 
heterogeneity was assessed by the I2 statistic (interpreted as low <0.25, moderate 0.50 and high >0.75). 
Genomic locations are given in NCBI Build 37/UCSC hg19 coordinates. For genome-wide significance, a 
limit of p< 5x10-8 was used. 
 
In order to test homogeneity of the results between AL amyloidosis and MM ASSET analysis was performed 
14. This method explores all possible subsets for negative, positive, or null associations, identifying the 
subset with the strongest association signal; it also accounts for the multiple tests required by the subset 
analysis.  
 
To investigate chromatin state segmentation profiles (ChromHMM) and 3-dimentional interactions (Hi-C) at 
risk loci we made use of the ENCODE project data on cell lines, including lymphoblastoid cells (GM12878).  
We also used HaploReg v4.1 (www.broadinstitute.org/mammals/haploreg) to evaluate the regulatory nature 
and the possible functional effects of SNPs and their proxies r2 ≥ 0.8, or 0.95 15.  All relevant data available 
in HaploReg were considered in the SNP search but when multiple cell types were listed data on 
hematologic cell types were reported. Association profiles were visualized using the Locuszoom 16 in 
conjunction with the UCSC genome browser 17. Z score calculated for SNPs as log OR divided by standard 
error 18.  
 
RESULTS  
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We selected 9 clinical profiles for a specific analysis of GWAS data (Table 1). Among Ig related profiles, λ 
any (with or without heavy chains) was the most common one, found in 930 patients. λ/κ LCO was found in 
535 patients. Kidney and heart profiles were the largest organ profiles, including over 800 patients each, and 
liver profile was the smallest with only 194 patients. The median diagnostic ages differed minimally, from 62 
to 66 years. The male-female ratio was 1.37 overall and it did not appreciably differ between the profiles. In 
the bottom of Table 1 data on the MM cohorts are given. 
  
Association analysis and comparison with MM 
 
We carried out a systematic association analysis of each of the 9 clinical profiles against controls in each of 
the 3 cohorts. Manhattan plots are shown for joint analysis in 4 clinical profiles with genome-wide 
associations. In the liver profile a genome-wide association, based on imputed SNPs, was noted in 
chromosome 11 but it had a MAF of 1%; thus few individuals had the variant allele and the association was 
considered no further.  
 
Among Ig profiles, the λ/κ LCO and the λ LCO profiles showed a strong association with SNP rs9344 (Table 
2). The OR for rs9344 OR in the λ/κ LCO profile was 1.62 (p=1.99x10-12) and in the λ LCO profile it was 
1.70 (p=1.29x10-11). The weakest association was noted for the IgG profile (1.20, 9.69x10-3), with non-
overlapping 95%CIs to the LCO profiles. For overall AL amyloidosis, the OR was 1.35 and for MM it was 
1.06, as reported earlier 12.  Z-scores are also listed because they will be used in figures to be shown later.  
  
For the IgG profile, rs10507419 reached genome-wide significance with an OR of 1.49 and p-value of 
5.63x10-8. The two subgroups IgG λ and IgG κ showed similar ORs (1.57 and 1.51, respectively) and IgG λ 
reached genome-wide significance of 2.90x10-8 (Table 3). ORs of profiles λ/κ LCO (0.90), λ LCO (0.91), 
liver (0.98) and κ any (1.00) differed significantly (non-overlapping 95%Cs) from the IgG profile. Among 
MM subtypes, the OR for IgG MM was 1.01 while the ORs for both IgG λ and IgG κ were 1.00. 
 
Genome-wide association was found for SNP rs6752376 in the heart & kidney profile (OR 1.54, p=2.88 x 10-
8) (Table 4). The profiles for kidney and heart only reached ORs of 1.24 and 1.27, respectively. ORs for liver 
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(0.98) and κ any (1.04) profiles differed significantly from the heart & kidney profile. The OR for MM was 
1.00.  
 
The liver profile rs7820212 reached genome-wide significance even with a small patient number (194) (OR 
1.86, p= 1.86 x 10-8) (Table 5). ORs of all other clinical profiles differed significantly from the liver profile. 
The OR for AL amyloidosis overall was 1.07 and for MM it was 1.04.  
 
Of note, there was no or at most moderate heterogeneity for any genome-wide significant associations in 
Tables 2 to 5 between the 3 AL amyloidosis cohorts as indicated by I2. The ORs of the significant 
associations did not change when stratified for age and sex.      
 
We assessed the associations of the previously described 10 putative candidate SNPs from the combined AL 
amyloidosis cohorts with each of the 9 profiles 12.  With the exception of SNP rs9344 (Table 2) no other SNP 
associated specifically with AL amyloidosis defined by a clinical profile. 
 
Biological interference  
 
Regional plots of association are shown in Fig. 2 for the genome-wide significant SNPs in 4 clinical profiles. 
For the λ/κ LCO profile, rs9344 on chromosome 11q13.3 maps to a splice site in the cyclin D1 gene as 
shown previously (Fig. 2A) 12. For the IgG profile, SNP rs10507419 on chromosome 13q13.2 maps within 
the LINC00457 gene (long intergenic non-protein coding RNA 457) of unknown function and resides 330 kb 
5’ of NBEA (neurobeachin) (Fig, 2B). ENCODE Hi-C data are lacking for rs10507419 but data are available 
for the linked SNP (r2=1.00) rs9529341, 1 kb away, showing long-range association within the NBEA gene 
(Supplementary Fig. 1, not included).   The SNP changes motif for transcription factor Pax-4. STEFAN: WE 
NEED DATA ON 13q deletion for this point.  
 
The heart & kidney profile risk SNP rs6752376 on chromosome 2p25.2 is located between two RNA genes, 
63 kb from LINC01247 (long intergenic non-protein coding RNA 1247) and 9.9 kb 3’ of ACO17053.1 (not 
shown in Fig. 2C); functions of both of these are unknown. rs6752376 is a moderate expression quantitative 
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trait locus (eQTL) (3.7x10-5) to human metabolic profile relating to serum concentration of pantothenate 19. 
According to HaploReg the SNP alters motifs for 3 transcription factors, Nkx2, Nkx3, PLZF. Liver profile 
SNP rs7820212 on chromosome 8q11.23 maps 28kb 3' of FAM150A (family with sequence similarity 150 
member A). 116 kb away is the locus for RB1CC1 (RB1 inducible coiled-coil 1). The SNP changes motif for 
transcription factor CEBPB. 
 
DISCUSSION 
 
The recent GWAS on these 3 AL amyloidosis cohorts reported 4 SNPs reaching (or almost reaching) a 
genome-wide significance 12. With the exception of the most significant SNP, rs9344, none of the other 3 
were associated with the defined 9 clinical profiles, probably because of decreased patient numbers. 
Interestingly, 3 completely new profile-specific genetic loci were identified with homogeneous results from 
the 3 cohorts. Independent associations of rs9344 with the two LCO profiles and of rs10507419 with the two 
IgG profiles show internal consistency.      
 
The preferential association of rs9344 with LCO profiles could possibly be explained by the association of 
this SNP with translocation (11;14) and the resulting disturbance of IgH production in AL amyloidosis and 
MM 12, 20, 21. However no light chain excess has been reported in t(11;14) AL amyloidosis 22, 23. Data on MM 
cell line have suggested that compromised production of IgH leads to excess production of free light chains 
24. How rs9344 could interfere with IgH production independent of t(11;14) remains enigmatic. Risk allele G 
at the splice site of cyclin D1 encodes a full length cyclin D1 which has many functions, including 
involvement in double-strand repair with RAD51, BRCA1 and BRCA2 and thus a possible interference with 
the class switch recombination for IgH 25, 26.  Curiously, while the LCO profiles were strongly associated 
with rs9344, the weakest association was noted for the IgG profile. Conversely, rs10507419 was strongly 
associated with the IgG profiles while weakly opposite associations were found with this SNP and the LCO 
profiles. rs10507419 on chromosome 13q13.2 maps close to the NBEA locus (13q13.3) which is a fragile site 
causing deletion of the telomeric end of chromosome 13q in patients with MM, MGUS and AL-amyloidosis 
22, 27-29. We found in Hi-C data that rs10507419 shows long-range association with the NBEA locus. 
Occasionally NBEA is fused with the tip of chromosome 8q24 containing PVT1 30. The translocation may 
interfere with expression of RB1 which is located at 13q14.2 29.  
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The possible functions of rs6752378 SNP associated with heart & kidney profile are unknown as are those 
for the adjacent RNA genes LINC01247 and ACO17053.1. The SNP may influence serum concentration of 
pantothenate but how this might be related to the heart & kidney profile remain unknown 19. Liver profile 
SNP rs7820212 on chromosome 8q11.23 maps close to FAM150A, which is a ligand for receptor tyrosine 
kinases leukocyte tyrosine kinase (LTK) and anaplastic lymphoma kinase (ALK). These belong to the insulin 
receptor superfamily, and their aberrant activation has been described in many cancers, such as non-small 
lung cancer and neuroblastoma in which ALK mutations are common 31, 32. Fusion genes of ALK are often 
found in lymphomas with resulting downstream activation of the Ras/Raf/MEK/ERK pathway 33. rs7820212 
is adjacent to the RB1CC1 gene which encodes a protein interacting with pathways involved in regulation of 
cell growth, proliferation, apoptosis, autophagy, and cell migration 34, 35. It has tumor suppressor properties 
in enhancing RB1 (retinoblastoma 1) gene expression in cancer cells and promoting senescence 36. The SNP 
changes the binding motif for CEBPB, which is an important transcription factor regulating the expression 
of genes involved in immune and inflammatory responses. CEBPB may regulate osteoclast activity in MM 
and through redundant functions with CEBPA it may be involved in multiple cellular processes in 
hematopoietic cells 37, 38.  
 
In conclusion, 4 SNPs reached genome-wide associations in clinical profile-specific AL amyloidosis. While 
the associations were internally consistent and homogeneous between the 3 cohorts the underlying 
mechanisms remain speculative but tangible. For rs9344 the preference for LCO amyloidosis is another lead 
to mechanistic understanding.    
 
 
CONFLICT OF INTEREST STATEMENT 
The authors declare no competing financial interests. 
 
ACKNOWLEDGEMENTS  
 
Funding was provided by the German Cancer Aid, the Harald Huppert Foundations, The German Federal 
Ministry of Education and Research (eMed, Cliommics 01ZX1309B), the Multiple Myeloma Research 
Foundation, the Heinz Nixdorf Foundation (Germany), the Ministerium für Innovation, Wissenschaft und 
9 
 
Forschung des Landes Nordrhein-Westfalen and the Faculty of Medicine University Duisburg-Essen. This 
study made use of genotyping data on the 1958 Birth Cohort generated by the Wellcome Trust Sanger 
Institute (http://www.wtccc.org.uk). 
 
 
Supplementary Information accompanies this paper on the Leukemia website 
 
REFERENCES 
 
1. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 
2011; 29: 1924-1933. 
 
2. Ramirez-Alvarado M. Amyloid formation in light chain amyloidosis. Current topics in medicinal 
chemistry 2012; 12(22): 2523-2533. 
 
3. Blancas-Mejia LM, Ramirez-Alvarado M. Systemic amyloidoses. Annual review of biochemistry 2013; 82: 
745-774. 
 
4. Gertz M. Immunoglobin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and 
management Am J Hematol 2011; 86: 181-186. 
 
5. Hemminki K, Li X, Forsti A, Sundquist J, Sundquist K. Incidence and survival in non-hereditary 
amyloidosis in Sweden. BMC Public Health 2012; 12: 974. 
 
6. Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, et al. Systemic amyloidosis in 
England: an epidemiological study. Br J Haematol 2013; 161: 525-532. 
 
7. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of 
undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus 
perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010 Jun; 
24(6): 1121-1127. 
 
8. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-596. 
 
9. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 2007; 
20: 637-664. 
 
10. Siragusa S, Morice W, Gertz MA, Kyle RA, Greipp PR, Lust JA, et al. Asymptomatic immunoglobulin 
light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with 
multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. Ann Hematol 
2011; 90: 101-106. 
10 
 
 
11. Weinhold N, Forsti A, da Silva Filho MI, Nickel J, Campo C, Hoffmann P, et al. Immunoglobulin light-
chain amyloidosis shares genetic susceptibility with multiple myeloma. Leukemia 2014 Jul 3; 28: 2254-2256. 
 
12. da Silva Filho MI, Försti A, Weinhold N, Meziane I, Campo C, Huhn S, et al. Genome-wide association 
study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison to myeloma. . Leukemia 
2017. 
 
13. Schonland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, et al. Immunohistochemistry 
in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012 Jan 
12; 119(2): 488-493. 
 
14. Bhattacharjee S, Rajaraman P, Jacobs KB, Wheeler WA, Melin BS, Hartge P, et al. A subset-based 
approach improves power and interpretation for the combined analysis of genetic association studies of 
heterogeneous traits. Am J Hum Genet 2012 May 4; 90(5): 821-835. 
 
15. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory 
motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012 Jan; 40(Database issue): D930-
934. 
 
16. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional 
visualization of genome-wide association scan results. Bioinformatics 2010; 26: 2336-2337. 
 
17. Speir ML, Zweig AS, Rosenbloom KR, Raney BJ, Paten B, Nejad P, et al. The UCSC Genome Browser 
database: 2016 update. Nucleic Acids Res 2016 Jan 04; 44(D1): D717-725. 
 
18. Li YR, Li J, Zhao SD, Bradfield JP, Mentch FD, Maggadottir SM, et al. Meta-analysis of shared genetic 
architecture across ten pediatric autoimmune diseases. Nat Med 2015 Sep; 21(9): 1018-1027. 
 
19. Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wagele B, et al. Human metabolic individuality 
in biomedical and pharmaceutical research. Nature 2011 Aug 31; 477(7362): 54-60. 
 
20. Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M, et al. Relationship between 
elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma. Leukemia 
2010 Aug; 24(8): 1498-1505. 
 
21. Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, et al. The CCND1 G870A 
polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma Nature Genet 2013; 45: 522-525. 
 
22. Bochtler T, Hegenbart U, Cremer FW, Heiss C, Benner A, Hose D, et al. Evaluation of the cytogenetic 
aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined 
significance reveals common pathways of karyotypic instability. Blood 2008; 111: 4700-4705. 
 
23. Muchtar E, Dispenzieri A, Kumar SK, Ketterling RP, Dingli D, Lacy MQ, et al. Interphase fluorescence in 
situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and 
treatment category. Leukemia 2016 Dec 16. 
11 
 
 
24. Magrangeas F, Cormier ML, Descamps G, Gouy N, Lode L, Mellerin MP, et al. Light-chain only multiple 
myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood 
2004 May 15; 103(10): 3869-3875. 
 
25. Gostissa M, Alt FW, Chiarle R. Mechanisms that promote and suppress chromosomal translocations in 
lymphocytes. Annu Rev Immunol 2011; 29: 319-350. 
 
26. Pestell RG. New Roles of Cyclin D1. The American Journal of Pathology 2013 7//; 183(1): 3-9. 
 
27. Bochtler T, Hegenbart U, Heiss C, Benner A, Moos M, Seckinger A, et al. Hyperdiploidy is less frequent 
in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated 
with translocation t(11;14). Blood 2011 Apr 7; 117(14): 3809-3815. 
 
28. Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, et al. Prognostic impact of 
cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood 
2016 Jul 28; 128(4): 594-602. 
 
29. O'Neal J, Gao F, Hassan A, Monahan R, Barrios S, Kilimann MW, et al. Neurobeachin (NBEA) is a target 
of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma. Experimental 
hematology 2009 Feb; 37(2): 234-244. 
 
30. Nagoshi H, Taki T, Hanamura I, Nitta M, Otsuki T, Nishida K, et al. Frequent PVT1 rearrangement and 
novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality. Cancer 
Res 2012 Oct 1; 72(19): 4954-4962. 
 
31. Guan J, Umapathy G, Yamazaki Y, Wolfstetter G, Mendoza P, Pfeifer K, et al. FAM150A and FAM150B 
are activating ligands for anaplastic lymphoma kinase. eLife 2015 Sep 29; 4: e09811. 
 
32. Reshetnyak AV, Murray PB, Shi X, Mo ES, Mohanty J, Tome F, et al. Augmentor alpha and beta 
(FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor 
interactions. Proc Natl Acad Sci U S A 2015 Dec 29; 112(52): 15862-15867. 
 
33. Roskoski R, Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological 
inhibition. Pharmacological research 2013 Feb; 68(1): 68-94. 
 
34. Pietrocola F, Izzo V, Niso-Santano M, Vacchelli E, Galluzzi L, Maiuri MC, et al. Regulation of autophagy 
by stress-responsive transcription factors. Semin Cancer Biol 2013 Oct; 23(5): 310-322. 
 
35. Lebovitz CB, Robertson AG, Goya R, Jones SJ, Morin RD, Marra MA, et al. Cross-cancer profiling of 
molecular alterations within the human autophagy interaction network. Autophagy 2015; 11(9): 1668-1687. 
 
36. Suraneni MV, Moore JR, Zhang D, Badeaux M, Macaluso MD, DiGiovanni J, et al. Tumor-suppressive 
functions of 15-Lipoxygenase-2 and RB1CC1 in prostate cancer. Cell cycle (Georgetown, Tex) 2014; 13(11): 
1798-1810. 
 
12 
 
37. Fuchs O, Kostecka A, Provaznikova D, Krasna B, Brezinova J, Filkukova J, et al. Nature of frequent 
deletions in CEBPA. Blood cells, molecules & diseases 2009 Nov-Dec; 43(3): 260-263. 
 
38. Tucci M, Stucci S, Savonarola A, Ciavarella S, Cafforio P, Dammacco F, et al. Immature dendritic cells in 
multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation. Br J Haematol 
2013 Jun; 161(6): 821-831. 
 
 
13 
 
 
Table 1. Number of AL amyloidosis and multiple myeloma patients according to clinical profiles 
 Clinical profiles German Britishc Italian Joined 
Median age  
(range) in yearsa 
Sex-ratiob 
Overall AL amyloidosis 562 410 257 1129 64 (30-87) 1.37:1 
Ig profiles c IgG 194 157 96 447 66 (30-87) 1.19:1 
 
IgG λ  160 116 69 345 66 (30-87) 1.16:1 
 
IgG κ  34 24 27 85 66 (40-85) 1.30:1 
 
λ any 438 304 188 930 64 (30-87) 1.38:1 
 
κ any 122 74 69 265 65 (38-87) 1.28:1 
 
λ/κ LCO 312 96 127 535 62 (37-84) 1.49:1 
  λ LCO 231 84 89 404 62 (37-84) 1.59:1 
Organ profiles  Kidney 358 320 166 844 64 (30-87) 1.30:1 
 
Heart 396 239 200 835 64 (34-87) 1.44:1 
 
HK 180 140 106 426 63 (38-87) 1.39:1 
  Liver 105 57 32 194 63 (34-87) 1.49:1 
Overall  multiple myeloma 1508  2282 - 3790 63 (27-89) 1.41:1 
Ig profiles IgG MM 748 - - - 57 (30-72) 1.44:1 
  IgG λ MM 200 - - - 58 (33-72) 1.17:1 
  IgG κ MM 548 - - - 57 (30 -72) 1.55:1 
a: Median age of the joined cohort.  
b: Sex-ratio is calculated as male:female ratio for the joined cohort. 
c: Data on some clinical profiles were missing in the British cohort.  
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Table 2. Summary statistics for the λ/κ LCO risk allele G of rs9344 in clinical profiles 
Profiles Number of cases Odds ratio 95% CI a P-value b I2 c Z-score  
Overall AL 1129 1.35 1.23-1.48 7.80 x 10-11 0.36 6.51 
IgG 447 1.20 1.05-1.38 9.69 x 10-3 0.00 2.59 
λ any 930 1.40 1.27-1.55 9.28 x 10-11 0.00 6.48 
κ any 265 1.33 1.11-1.59 2.03 x 10-3 0.00 3.09 
λ/κ LCO 535 1.62 1.42-1.85 1.99 x 10-12 0.00 7.04 
λ LCO 404 1.70 1.46-1.98 1.29 x 10-11 0.00 6.77 
Kidney 844 1.34 1.20-1.48 6.89 x 10-8 0.20 5.40 
Heart 835 1.39 1.24-1.54 2.91 x 10-9 0.49 5.94 
HK 426 1.31 1.14-1.52 2.14 x 10-4 0.38 3.70 
Liver 194 1.40 1.14-1.73 1.63 x 10-3 0.00 3.15 
Overall MM  3790 1.06 1.00-1.12 4.00 x 10-2 0.61 2.09 
a CI, confidence interval 
b P-value based on the meta-analysis of the three patient cohorts in AL amyloidosis, and two 
patient cohorts in multiple myeloma 
c I2 proportion of total variance due to heterogeneity 
Genome-wide significant associations are indicated in bold  
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Table 3. Summary statistics for the IgG profile risk allele A of rs10507419 of in clinical profiles 
Profiles N cases Odds ratio 95% CI a P-value b I2 c Z-score  
Overall AL 1129 1.13 1.03-1.25 1.15 x 10-2 0.00 2.53 
IgG 447 1.49 1.29-1.72 5.63 x 10-8 0.49 5.43 
IgG λ 345 1.57 1.34-1.85 2.90 x 10-8 0.42 5.55 
IgG κ 85 1.51 1.21-1.89 2.39 x 10-4 0.67 3.68 
λ any 930 1.18 1.06-1.32 2.20 x 10-3 0.00 3.06 
κ any 265 1.00 0.82-1.22 9.88 x 10-1 0.00 0.02 
λ/κ LCO 535 0.90 0.78-1.04 1.63 x 10-1 0.00 -1.39 
λ LCO 404 0.91 0.77-1.07 2.46 x 10-1 0.35 -1.16 
Kidney 844 1.18 1.06-1.32 2.69 x 10-3 0.00 3.00 
Heart 835 1.16 1.04-1.30 1.02 x 10-2 0.00 2.57 
HK 426 1.33 1.15-1.55 1.81 x 10-4 0.38 3.75 
Liver 194 0.98 0.78-1.24 9.00 x 10-1 0.00 -0.13 
Overall MM  3790 1.06 1.00-1.13 4.47 x 10-2 0.03 2.00 
IgG MM  748 1.01 0.88-1.15 9.35 x 10-1 - 0.08 
IgG λ MM 200 1.00 0.80-1.26 9.56 x 10-1 - 0.06 
IgG κ MM 548 1.00 0.86-1.16 9.40 x 10-1 - 0.07 
aCI, confidence interval 
bP-value based on the meta-analysis of three patient cohorts in AL amyloidosis, and two patient cohorts 
in multiple myeloma; the IgG profiles of MM are based on only German cohort 
cI2 proportion of total variance due to heterogeneity 
Genome-wide significant associations are indicated in bold 
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Table 4. Summary statistics for the HK profile risk allele T of rs6752376 in clinical profiles 
Profiles Number of cases Odds ratio 95% CI a P-value b I2 c Z-score  
Overall AL 1129 1.17 1.06-1.28 9.96 x 10-4 0.75 3.29 
IgG 447 1.20 1.04-1.39 1.12 x 10-2 0.33 2.54 
λ any 930 1.24 1.12-1.38 5.20 x 10-5 0.67 4.05 
κ any 265 1.04 0.87-1.25 6.59 x 10-1 0.10 0.44 
λ/κ LCO 535 1.20 1.05-1.37 7.78 x 10-3 0.46 2.66 
λ LCO 404 1.25 1.08-1.46 3.52 x 10-3 0.54 2.92 
Kidney 844 1.24 1.11-1.38 8.62 x 10-5 0.71 3.93 
Heart 835 1.27 1.14-1.42 1.50 x 10-5 0.30 4.31 
HK 426 1.54 1.32-1.79 2.88 x 10-8 0.07 5.55 
Liver 194 0.98 0.80-1.21 8.86 x 10-1 0.00 -0.14 
Overall MM  3790 1.00 0.94-1.06 9.25 x 10-1 0.37 -0.09 
aCI, confidence interval 
bP-value based on the meta-analysis of three patient cohorts in AL amyloidosis, and two patient 
cohorts in multiple myeloma 
cI2 proportion of total variance due to heterogeneity 
Genome-wide significant associations are indicated in bold 
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Table 5. Summary statistics for the liver profile risk allele A of rs7820212 in clinical profiles 
Profiles Number of cases Odds ratio 95% CI a P-value b I2 c Z-score  
Overall AL 1129 1.07 0.98-1.17 1.40 x 10-1 0.19 1.48 
IgG 447 1.00 0.87-1.15 9.63 x 10-1 0.00 0.05 
λ any 930 1.10 0.99-1.21 6.32 x 10-2 0.52 1.86 
κ any 265 0.97 0.81-1.16 7.49 x 10-1 0.05 -0.32 
λ/κ LCO 535 1.13 0.99-1.29 6.67 x 10-2 0.26 1.83 
λ LCO 404 1.14 0.98-1.32 8.30 x 10-2 0.61 1.73 
Kidney 844 1.10 0.99-1.22 8.33 x 10-2 0.36 1.73 
Heart 835 1.09 0.98-1.21 1.07 x 10-1 0.00 1.61 
HK 426 1.02 0.88-1.17 8.04 x 10-1 0.06 0.25 
Liver 194 1.86 1.50-2.31 1.86 x 10-8 0.04 5.63 
Overall MM  3790 1.04 0.98-1.10 1.81 x 10-1 0.00 1.34 
aCI, confidence interval 
bP-value based on the meta-analysis of three patient cohorts in AL amyloidosis, and two patient 
cohorts in multiple myeloma 
cI2 proportion of total variance due to heterogeneity 
Genome-wide significant associations are indicated in bold 
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LEGENDS TO FIGURES 
 
Figure 1. Manhattan plots of association analysis for AL amyloidosis clinical profiles with 
genome-wide significant results. A) λ/κ LCO profile; B) IgG profile; C) heart & kidney profile; 
D) liver profile. The x-axis shows the chromosomal position and the y-axis is the significance (–
log10 P; 2-tailed) of association derived by logistic regression. The red line shows the genome-
wide significance level (5 × 10−8) and the blue line shows suggestive significance level (1 × 10-5). 
The significant/top SNPs are labeled. 
 
Figure 2. Regional association plots showing the significant/top SNPs in the four AL amyloidosis 
clinical profiles. A) λ/κ LCO profile; B) IgG profile; C) heart & kidney profile; D) liver profile. The x-
axis shows the chromosomal position as Mb and the mapped genes annotated from the UCSC genome 
browser. The y-axis shows the significance (–log10 P; 2-tailed) on the left and recombination rates 
(light blue lines) on the right. The reference SNP is labeled and colored purple, the rest of the SNPs 
are colored based on their r2 to the reference SNP, on a shown scale, based on pairwise r2 values from 
HapMap CEU. Square-shaped SNP symbols represent genotyped SNPs and circle-shaped SNPs 
represent imputed ones.  
 
Supplementary Figure : Z-diagrams 
Supplementary Figure : Hi-C  
Supplementary Figure : Forest plot for each SNP considering amyloidosis and multiple myeloma 
results. 
 
 
 
 
